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Glycated haemoglobin (HbA1c) test has been increasingly promoted as an alternative to
fasting plasma glucose (FPG) or oral glucose tolerance test (OGTT) to diagnose dysglycae-
mia but its performance in HIV-infected Africans has yet to be established. This study aimed
to assess the diagnostic accuracy of HbA1c for dysglycaemia including FPG-defined and
OGTT-defined dysglycaemia, and OGTT-defined diabetes in HIV-infected Africans, and the
effect of HbA1c-predicted dysglycaemia on Joint Interim Statement (JIS)-based prevalent
metabolic syndrome (MS).
Methods
A cross-sectional study included HIV-positive patients recruited across public healthcare
facilities in the Western Cape. The recommended HbA1c cut-points were tested alongside
the optimal cut-points obtained from receiver operating characteristic curve analyses, while
the agreement between the MS criteria were assessed using kappa statistic.
Results
748 participants (157 men), median age 38 years, 93% on anti-retroviral drugs were
included. The optimal HbA1c cut-points of 5.75% (39.3 mmol/mol) showed 54% sensitivity,
84% specificity for FPG-defined dysglycaemia, and 52% sensitivity, 85% specificity for
OGTT-defined dysglycaemia. The HbA1c value of 5.85% (40.4 mmol/mol) (63% sensitivity,
99% specificity) was optimal for diabetes. The internationally advocated cut-point of 6.5%
(48 mmol/mol) had 37% sensitivity and 99% specificity for diabetes, while HbA1c�5.7%
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(�39 mmol/mol) yielded similar performance with the study-specific cut-point for any dysgly-
caemia. MS prevalence by the JIS criteria (28.2%) increased to 29.7% when using HbA1c
�5.75% (�39.3 mmol/mol) and to 32.9% with HbA1c�5.7% (�39 mmol/mol); agreement
between the original and modified criteria was generally good.
Conclusions
This study agrees with the internationally recommended HbA1c cut-point for detecting dys-
glycaemia, but not for diabetes in HIV-infected Africans. In line with previous studies in gen-
eral African populations, our findings suggest that similar factors interfere with HbA1c
values regardless of HIV infection status. Replacing FPG-based with HbA1c-predicted dys-
glycaemia in the JIS criteria to diagnose MS is feasible in HIV-infected Africans.
Introduction
Measuring fasting plasma glucose (FPG) levels or performing an oral glucose tolerance test
(OGTT), are the currently recommended tools for diagnosing diabetes and other categories of
dysglycaemia [1,2]. However, these tests are inconvenient requiring an overnight fast and the
OGTT is cumbersome as it necessitates a 2-hour waiting period. Given these inconveniences
and the day-to-day variability in glucose, there is a need for a reliable, high performance, con-
venient and low-cost alternative. Glycated haemoglobin (HbA1c), which reflects the average
plasma glucose concentration over the previous 8–12 weeks, has been used in diabetes care to
monitor glucose control [3]. Notably, it has also been suggested for use as an alternate diagnos-
tic tool [1]. Previously, the test was expensive and there were concerns about accuracy of mea-
surements. However, since 2009, with advances in technology, assay standardisation and costs
have improved. HbA1c affords the convenience of not requiring an overnight fast nor a wait-
ing period. It can be performed at any time of the day and overcomes the day-to-day variability
in glucose levels [3]. Consequently, HbA1c is now increasingly considered for use as a diagnos-
tic tool for diabetes and high-risk of diabetes [1,2].
The use of a convenient test that does not require pre-planning nor a waiting period would
be particularly advantageous in Sub-Saharan Africa where there are numerous barriers to
healthcare service access. These include travelling long distances and high out-of-pocket
expenses which prevent revisits, particularly at short intervals, and consequently, a large pro-
portion of individuals with diabetes remain undiagnosed in the region [4]. However, the abil-
ity of HbA1c to diagnose dysglycaemia in African populations has been variable [5].
Haemoglobinopathies, anaemia and haemolysis influencing the accuracy of HbA1c results are
frequent in Africa. Furthermore, the burden of HIV infection is high in Africa, and anaemia
and haemolysis are more common in HIV-infected individuals compared with the general
population [6,7]. However, the ability of HbA1c to accurately diagnose diabetes and other dys-
glycaemias in HIV-infected individuals has not yet been established.
Therefore, in the current study, we assessed the accuracy of HbA1c for diagnosing any dys-
glycaemia (impaired fasting glycaemia and/or impaired glucose tolerance) and screen-detected
diabetes in a population of South Africans living with HIV infection. Additionally, we assessed
the prevalence of metabolic syndrome (MS), defined by the Joint Interim Statement (JIS) crite-
ria, when HbA1c was used to diagnose hyperglycaemia instead of fasting glucose.
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Materials and methods
Design and population
The current study is based on cross-sectional data collected between March 2014 and February
2015; the methodological approach has been described in detail elsewhere [8]. In brief the par-
ticipants were recruited from public healthcare facilities in Cape Town (10) and the surround-
ing rural municipalities (seven) where the majority of residents were black and coloured [9],
using simple random sampling procedures without any stratification. Consenting HIV-posi-
tive men and women aged 18 years or older, and were not pregnant, breastfeeding, bedridden,
undergoing treatment for cancer, nor on corticosteroid treatment were included.
The study was approved by the South African Medical Research Council Ethics Committee,
according to Official Letter no. EC021-11/2013, and by the Health Research Office of the West-
ern Cape Department of Health, document no. RP 005/2014. All participants signed informed
consent forms prior to the study procedure. Data sharing was not included in the consent.
Data collection
The data were collected by a well-trained research team including clinicians, nurses and field-
workers, and captured on personal digital assistants (PDAs) onto a web-based respondent
driven sampling research management system [10]. This system used electronic case report
forms with built-in checks for quality control to ensure the quality and integrity of the data col-
lected in real-time. At the same time, the system allowed the participant’s data to be linked and
tracked throughout the research site via a unique barcode using BRYANT Research systems
software [10]. Data on socio-demographic and medical history were obtained from a struc-
tured interviewer-administered questionnaire adapted from the WHO STEPwise approach to
Surveillance (STEPS) tool (S1 File). HIV-related information such as duration of diagnosed
HIV infection, CD4 counts and antiretroviral therapy (ART) regimens were from the partici-
pants’ records.
Measurements. Anthropometry was done using standardised techniques. Heights and
weights were measured with the participants in light clothing and without shoes. Blood pres-
sure (BP) were taken on the right arm, using a digital BP monitor (Omron, M6 Comfort, Neth-
erland) after seating the participant in a resting position for at least five minutes. Three BP
measurements were taken three minutes apart, and the average of 2nd and 3rd readings was
used in the analysis.
All participants who did not have a history of diabetes underwent a standard 2-hour 75
grams OGTT after an overnight fast. Plasma glucose levels were determined at fasting (FPG)
and at 2-hour post-OGTT (2h-PG). Blood samples were drawn and processed for laboratory
analyses. The concentrations of glucose and lipid were measured with an autoanalyser, Beck-
man Coulter AU 500 spectrophotometer, while hexokinase and enzymatic colorimetric meth-
ods were used to analyse plasma glucose and serum triglycerides and high density lipoprotein
cholesterol (HDL-C) respectively. HbA1c was measured using high-performance liquid chro-
matography (VARIANT II TURBO, EDTA tubes) in accordance with the National Glycohae-
moglobin Standardisation Programme (NGSP).
Definitions. The following dysglycaemia categories were defined: Raised FPG: FPG�5.6
mmol/L, raised 2h-PG: 2h-PG�7.8 mmol/L, and diabetes or screen-detected diabetes as
FPG�7.0 mmol/L and/or 2h-PG�11.1 mmol/L without previously diagnosed diabetes [11].
Participants with previously diagnosed diabetes were excluded from the data analyses.
MS components and their cutoffs were defined based on JIS criteria: increased waist cir-
cumference (WC): men�94 cm, women�80 cm; high triglycerides:�1.7 mmol/L; low
HbA1c for dysglycaemia screening in HIV
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HDL-C: men<1.03 mmol/L, women<1.3 mmol/L; raised BP:�130/85 mmHg or on hyper-
tensive medication; hyperglycemia: FPG�5.6 mmol/L or on glucose control agents [12].
Statistical analysis
The R statistical software version 3.3.1 (2016-06-21), (The R Foundation for Statistical Com-
puting Platform, Vienna, Austria) was used for data analyses. Continuous data are presented
as means (± standard deviation, SD) or medians (25th-75th percentiles), while categorical data
as frequencies and percentages. Mann-Whitney U test and chi square test were used to com-
pare men vs. women data. Kappa statistic was computed to assess the concordance between
the diagnostic criteria of MS: the JIS and those modified using HbA1c instead of FPG. The
kappa values are interpreted as poor (kappa�0.2), fair (kappa�0.4), moderate (kappa�0.6),
substantial (kappa�0.8), and very good (kappa>0.8).
The receiver operating characteristic curves (ROC) analyses were performed using the
“pROC” package. The optimal cut-point level of HbA1c was determined using two methods:
1) the closest top-left point and 2) the Youden’s index (J-point). 1) In the ROC analysis, pairs
of the true positive rate (sensitivity) and the false positive rate (1-specificity) and for every indi-
vidual cut-point are plotted. The shape of the ROC curve indicates the discriminative power
level of the test, and perfect discrimination is where the ROC curve passes through the upper-
left corner (100% sensitivity, 100% specificity). Therefore, when the ROC curve is closer to the
upper-left corner and the area under the curve (AUC) is larger, the overall accuracy of the test
is higher, and the cut-point nearest to the upper-left corner is defined as the optimal one. The
Youden’s index is computed as sensitivity + specificity– 1 and ranges from 0 to 1. Maximising
this index (J-point) allows finding an optimal cut-point independently from the outcome prev-
alence. The 95% confidence interval of the derived optimal cut-point was computed using
bootstrap sampling based on 2000 replicates.
The diagnostic accuracy of the derived cut-off level was assessed alongside American Diabe-
tes Association (ADA) / International Diabetes Federation (IDF) recommended thresholds by
computing a number of diagnostic performance measures including the sensitivity which is
the probability that a person has a positive test result given that of having a positive outcome;
the specificity, the probability that a person has a negative test result given that of having a neg-
ative outcome; the positive predictive value (PPV), the probability that a person has a positive
outcome given that of having a positive test result; the negative predictive value (NPV), the
probability that a person has a negative outcome given that of having a negative test result, and
the Youden’s index. All these calculations were done with the “epiR” package of R.
Results
General characteristics of the participants
Fig 1, which is the Standard of Reporting for Diagnostic Accuracy Studies (STARD) diagram,
demonstrates the flow of participants in the present study. The starting sample comprised 831
participants of which 83 had missing data on at least one component of the JIS-defined MS,
and were excluded. Therefore, the main analytic sample comprised 748 participants including
157 men and 591 women. Of these, 48 with missing 2h-PG data were excluded from the
OGTT-related analyses.
The clinical and biochemical characteristics of the participants are summarised in Table 1.
Their median age was 38 years (25th-75th percentiles: 35–42), and 93% were ART users. The
median CD4 count was 392 cells/mm3 (25th-75th percentiles: 240–604) and the median dura-
tion of diagnosed HIV infection was 5 years (25th-75th percentiles: 2–9). Women had higher
CD4 counts and longer duration of diagnosed HIV infection than men (both p�0.001). The
HbA1c for dysglycaemia screening in HIV
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median HbA1c was 5.5% (25th-75th percentiles: 5.2–5.8) [37 mmol/mol (25th-75th percentiles:
33–40)] with no difference between men and women (p = 0.344). Furthermore, women had
greater WC, BMI, systolic BP, higher levels of HDL-C, high-sensitivity C-reactive protein (hs-
CRP), but lower values of triglycerides, gamma-glutamyl transferase (gamma-GT) as well as
serum creatinine compared to men (all p�0.023). The overall prevalence of dysglycaemia was
17.6% based on FPG alone, and 19.6% based on OGTT. Nineteen participants (2.8%) were
identified with screen-detected diabetes; while 28 (3.7%) participants had known diabetes. The
prevalence of dysglycaemia, screen-detected diabetes and previously diagnosed diabetes did
not vary significantly among men and women (all p�0.305).
Optimal cut-point of HbA1c for dysglycaemia and diabetes
The AUCs for HbA1c to identify participants with dysglycaemia was 0.733 (95% confidence
interval [CI]: 0.682–0.784) for FPG-diagnosed dysglycaemia and 0.722 (95%CI: 0.670–0.774)
for OGTT-diagnosed dysglycaemia (Fig 2). The optimal HbA1c cut-point for either FPG or
OGTT-diagnosed dysglycaemia was 5.75% (95%CI: 5.35–5.75) [39.3 mmol/mol (35–39.3)].
Table 2 shows the performance of different HbA1c cut-points for detecting dysglycaemia and
screen-detected diabetes among participants. For FPG-defined dysglycaemia, the derived cut-
point was 5.75% (39.3 mmol/mol) with the following performance measures: sensitivity 54%
(95%CI: 44–62), specificity 84% (80–87), Youden’s index 0.37 (0.25–0.49), PPV 41% (34–49),
and NPV 89% (87–92). The cut-point 5.7% (39 mmol/mol), which is recommended by the
ADA and the IDF, showed a sensitivity of 58% (49–67), specificity 77% (73–80), Youden’s
index 0.35 (0.22–0.47), PPV 35% (29–42), and NPV 0.90 (0.87–0.92). For OGTT-defined dys-
glycaemia, the derived HbA1c cut-point of 5.75% (39.3 mmol/mol) yielded a sensitivity of 52%
Fig 1. STARD diagram describes the flow of the participants throughout the study analyses. aDGL, dysglycaemia is
based on fasting plasma glucose (FPG)�5.6 mmol/L; bDGL is based on FPG�5.6 mmol/L and/or 2h-plasma
glucose�7.8 mmol/L; Diabetes is defined as World Health Organization criteria (FPG�7.0 mmol/L and/or 2h-plasma
glucose�11.1 mmol/L).
https://doi.org/10.1371/journal.pone.0211483.g001
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(43–60), specificity 85% (81–88), Youden’s index 0.37 (0.23–0.45), PPV 48% (40–56), and
NPV 85% (82–88) while the cut-point of 5.7% (39 mmol/mol) gave a sensitivity of 56% (47–
65), specificity 78% (74–81), Youden’s index 0.34 (0.21–0.46), PPV 38% (31–45), and NPV
88% (85–91).
The AUC of HbA1c to diagnose participants with screen-detected diabetes was 0.797
(0.686–0.907) (Fig 2). The optimal cut-point was 5.85% (5.25–6.65) [40.4 mmol/mol (33.9–
49.2)], and the resultant performance measures were: sensitivity 63% (38–84), specificity 86%
(83–88), Youden’s index 0.49 (0.22–0.73), PPV 11% (6–19), and NPV 99% (97–100), (Table 2).
The HbA1c cut-point of 6.5% (48 mmol/mol), recommended by the ADA and IDF had a sen-
sitivity of 37% (16–62), specificity 99% (98–100), Youden’s index 0.36 (0.22–0.80), PPV 55%
(30–80), and NPV 98% (97–99), Table 2.
Prevalence of MS using FPG or HbA1c as the hyperglycaemia criterion
Fig 3 depicts the prevalence of MS according to the original and modified JIS using HbA1c
cut-points. Based on the original JIS criteria which uses FPG�5.6 mmol/L, the prevalence of
MS was 28.2% (211/748) overall, 16.6% (26/157) in men, and 31.3% (185/591) in women
Table 1. Cardio-metabolic risk and HIV-related characteristics in men and women.
Characteristics Overall (N = 748) Men (n = 157) Women (n = 591) P-value
Median (25th–75th percentiles)
Age (years) 38 (32–44) 41 (35–47) 37 (31–43) <0.001
Known diabetes, n (%) 28 (3.7) 8 (5.1) 20 (3.4) 0.315
Waist circumference (cm) 88 (78–98) 78.9 (74–88) 90 (80–101) <0.001
Body mass index (kg/m2) 26.3 (22.1–32) 21.4 (19.8–22.4) 28.3 (23.8–28.9) <0.001
Systolic blood pressure (mmHg) 117 (107–130) 123.5 (114.5–140) 115 (105.8–127) <0.001
Diastolic blood pressure (mmHg) 82 (75–91) 83 (76–94) 81.5 (74.8–89.8) 0.129







Fasting plasma glucose (mmol/L) 5 (4.6–5.4) 5.1 (4.8–5.5) 4.9 (4.6–5.4) 0.010
2h-plasma glucose (mmol/L) 5.3 (4.6–6.2) 5.15 (4.4–6.3) 5.4 (4.6–6.2) 0.262
FPG-based dysglycemia1, n (%) 127/720 (17.6) 28/149 (18.8) 99/571 (17.3) 0.678
OGTT based dysglycemia2, n (%) 132/672 (19.6) 32/141 (22.7) 100/531 (18.8) 0.305
Diabetes3, n (%) 19 (2.8) 2 (1.4) 17 (3.2) 0.392
Triglycerides (mmol/L) 1 (0.7–1.3) 1.12 (0.75–1.27) 0.97 (0.74–1.28) 0.023
HDL-C (mmol/L) 1.3 (1–1.5) 1.2 (1.0–1.5) 1.29 (1.08–1.52) 0.010
hs-CRP (mg/L) 5.6 (2.4–14.5) 4.9 (2.1–16.2) 5.6 (2.4–14.2) 0.728
gamma-GT (IU/L) 39 (26–66) 53 (30–96) 38 (25–58) <0.001
Creatinine (μmol/L) 58 (51–67) 70 (61–79) 56 (49–62) <0.001
HIV duration (years) 5 (2–9) 4 (2–7) 5 (2.5–9) <0.001
CD4 count (cells/mm3) 392(240–604) 272 (193–448) 410 (253–627) 0.001
ART-usage, n (%) 0.296
ART-naive 46/699 (6.6) 7/149 (4.7) 39/550 (7.1)
ART-treated 653/699 (93.4) 142/149 (95.3) 511/550 (92.9)
ART, antiretroviral therapy; BMI, body mass index; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; HIV, human immunodeficiency virus;
hs-CRP, high sensitivity C-reactive protein; gamma-GT, gamma-glutamyl transferase;
1FPG�5.6 mmol/L;
2FPG�5.6 mmol/L and/or 2h-plasma glucose�7.0 mmol/L;
3FPG�7.0 mmol/L and/or 2h-plasma glucose�11.1 mmol/L without previously diagnosed diabetes.
https://doi.org/10.1371/journal.pone.0211483.t001
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(p<0.001). Replacing FPG with HbA1c�5.75% (�39.3 mmol/mol) yielded the prevalence of
29.7% (222/748) overall, 15.3% (24/157) in men, and 33.5% (198/591) in women (p<0.001).
Out of 246 participants who were diagnosed with the MS based on either FPG or HbA1c
�5.75% (�39.3 mmol/mol)], 187 (76%) were identified by both criteria, 35 participants
(14.2%) met the HbA1c criteria only while 24 (9.7%) participants met the FPG criteria only,
[kappa = 0.81 (95%CI: 0.76–0.86)].
If HbA1c�5.7% (�39 mmol/mol) was used, the MS prevalence would be 32.9% (246/748)
overall, 18.5% (29/157) in men, and 36.7% (217/591) in women (p<0.001). Among 266 partici-
pants with MS according to either FPG or HbA1c [cut-point 5.7% (39 mmol/mol)], 72% were
Fig 2. ROC curve characteristics of HbA1c that corresponded with fasting plasma glucose (FPG)�5.6 mmol/L (A), FPG�5.6mmol/L or 2-hour oral
glucose tolerance test (OGTT)�7.8mmolL (B), and FPG�7.0mmol/L and 2-hour OGTT�11.1mmol/L (C) in HIV-infected participants without known
diabetes. The ROC curves show the same optimal cut-point of HbA1c of 5.75% (39.3 mmol/mol) for diagnosing dysglycaemia based on FPG (A) (AUC: 0.733,
sensitivity: 54%, specificity: 84%) or based on OGTT (B) (AUC: 0.722, sensitivity: 52%, specificity: 85%), and the optimal HbA1c of 5.85% (40.4 mmol/mol) for
screen-detected diabetes (C) (AUC: 0.797, sensitivity: 63%, specificity: 86%).
https://doi.org/10.1371/journal.pone.0211483.g002
Table 2. Performances of HbA1c corresponding with dysglycaemia, and screen-detected diabetes among the participants without history of diabetes from ROC
curve analysis.

























































FPG, fasting plasma glucose; AUC, area under the curve; Sensitivity = TP/(TP+FN); Specificity = TN/(TN+FP); Youden’s index = (sensitivity + specificity)– 1; PPV,
positive predictive value = TP/(TP+FP); NPV, negative predictive value = TN/(TN+FN); where TP, true positive; FP, false positive; TN, true negative; FN, false negative.
https://doi.org/10.1371/journal.pone.0211483.t002
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diagnosed by both criteria, 20.7% by only HbA1c and 7.5% by FPG, [kappa = 0.76 (0.71–
0.81)]. Fig 3.
Discussion
The present study is among the first to examine the performance of HbA1c as a diagnostic test
for dysglycaemia or diabetes in a sub-Saharan African population living with HIV infection.
Our key findings are the following: 1) HbA1c had an acceptable-to-good discriminatory ability
to detect prevalent dysglycaemia (impaired fasting glycaemia, and/or impaired glucose toler-
ance) and screen-detected diabetes; 2) The study-specific optimal HbA1c cut-point to detect
the presence of dysglycaemia was not appreciably different from the advocated cut-point by
the ADA and IDF, while the optimal cut-point to detect screen-detected diabetes was lower
than that recommended by the two organisations, but in line with previous studies in the gen-
eral population in Africa [5, 13]; 3) Replacing FPG-based with HbA1c-predicted dysglycaemia
in the JIS MS criteria led to marginally higher prevalence estimates, with generally good agree-
ment between the original JIS and the modified criteria.
Although HbA1c has been recommended by the ADA and IDF as an alternative test for
diagnosing diabetes and individuals at high risk for diabetes, its applicability and suitable
thresholds in various populations remain unresolved [14]. In the present study, the optimal
cut-point of HbA1c for detecting diabetes was lower than the one recommended by the ADA/
IDF but within the range of the cut-point found in a mixed-ancestry South African population
[5]. The data in that study were from 819 participants with median age of 52 and residing in
the local community [5]. We found no similar data from HIV-infected Africans for direct
comparison. Nonetheless, our findings agreed with a study from the United State which
showed that the HbA1c threshold of 6.5% (48 mmol/mol) was insensitive but highly specific
while the HbA1c level of 5.8% (40 mmol/mol) was ideal for diagnosing diabetes in HIV-
Fig 3. Metabolic syndrome by the Joint Interim Statement criteria: Comparing prevalence using dysglycaemia
criteria of fasting plasma glucose with HbA1c in participants without knowing diabetes. The first row shows
prevalence of MS based on JIS-HbA1c�5.75% (�39.3 mmol/mol) and JIS criteria, overall (A1), men (B1), women
(C1); the second row shows the prevalence of MS based on JIS-HbA1c�5.7% (�39 mmol/mol) and JIS criteria, overall
(A2), men (B2), women (C2).
https://doi.org/10.1371/journal.pone.0211483.g003
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infected patients [15]. Furthermore, a pooled analysis of data from 96 population-based health
examination surveys yielded HbA1c 6�5% or more had a pooled sensitivity of 30�5% compared
with FPG or-2hOGTT-based diabetes, with the heterogeneity that could not explained by the
preselected study-level characteristics [14].
For the detection of dysglycaemia, the derived HbA1c cut-point of 5.75% (39.3 mmol/mol)
is similar to that found in mixed-ancestry South Africans [13] and not appreciably different
from the 5.7% (39 mmol/mol) recommended by the ADA/IDF. It should be understood that
the present and previous studies in South Africa tend to agree more on HbA1c-based diagnosis
for dysglycaemia than diabetes. It has been reported that HbA1c may not accurately reflect gly-
caemia in individuals with abnormal haemoglobin [16]. Iron and vitamin B12 deficiency with
and without anaemia have been reported to reduce erythropoiesis, and thus reduce erythrocyte
turnover which lead to increase in HbA1c values independently of glucose levels [16]. Some
studies have suggested that low-grade haemolysis might contribute to lower HbA1c value at a
given glucose level in HIV-infected patients than HIV-uninfected individuals [6,17]. Despite
the above, the derived cut-points in our study appear consistent with those obtained in the
local general population [5,13]. This suggests that the factors that influence HbA1c values in
African populations are unlikely to differ by HIV status. In part, this similarity could be
explained by relatively short duration of HIV infection (median diagnosed HIV was 5 years),
and successful HIV treatment (majority of the participants was on first-line ART regimen)
among the present study participants. Nonetheless, small sample size preclude reliable analyses
stratified by CD4 count.
Replacing FPG with HbA1c showed the change in MS prevalence to be marginal, with
HbA1c diagnosing slightly more people than FPG while missing only a tiny proportion diag-
nosed by FPG in the present study. This suggests that HbA1c could be used as the hyperglycae-
mia criterion for MS in HIV-infected individuals. This finding is essential in African
populations, especially people infected with HIV. Although MS definitions have used FPG as
the diagnostic criterion for hyperglycaemia, African studies have found FPG alone to be an
inadequate screening test for dysglycaemia or diabetes in general populations since it misses a
significant proportion of individuals who tend to only have 2-hour abnormalities [18]. Replac-
ing FPG with HbA1c to identify hyperglycaemia or diabetes in the diagnosis of MS in African
populations has relevance as HbA1c could possibly identify individuals who may also have
dysglycaemia on the 2-hour OGTT while overcoming the challenges of performing the OGTT
in these specific populations. This is particularly relevant for Africans living with HIV infec-
tion who regularly require routine screening for cardiovascular health. Indeed, the require-
ment for an overnight fasting and the long waiting periods for the completion of the OGTT
would be problematic for both HIV-care providers and the patients.
Strengths and limitations
Our study had some limitations with the wide confidence interval of the optimal HbA1c cut-
point for diagnosing diabetes indicating a lack of statistical power due to the small sample size.
The absence of an HIV-uninfected group and of external validation limit the recommendation
of our results for application in routine setting. Another limitation was that data on erythro-
cyte abnormalities were not collected in the present study. Nonetheless, our study has numer-
ous strengths. Apart from a multiple-clinic study, this is the first to examine the performance
of HbA1c as a diagnostic test for glycaemic disorders and the MS in a sub-Sahara African pop-
ulation living with HIV infection. Another strength was the availability of not only FPG but
also 2h-PG levels for the analyses of HbA1c cut-points corresponding to both FPG and 2h-
OGTT.
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Conclusions
In this HIV-infected African population, the optimal HbA1c cut-point to detect the presence
of dysglycaemia was not appreciably different from the advocated cut-point by the ADA and
IDF, while the optimal cut-point to detect screen-detected diabetes was lower than that recom-
mended by the two organisations. Importantly, these findings are in line with previous studies
in the general population in Africa, suggesting that factors influencing HbA1c values are likely
to be similar in African HIV-infected and uninfected populations. Our study findings further
support that replacing the FPG criterion in the JIS MS definition with HbA1c will have only
marginal effects on MS prevalence, while facilitating the screening of the condition. However,
these findings need to be confirmed by other studies in HIV-infected African populations. Ide-
ally, such studies should be nested with interventions to mitigate the risk, using evidence gen-
erated from the general population.
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